Product Description
An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities. Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types. This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fenretinide)
Mechanisms of Action: Vitamin A Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Laurent
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: COVID-19|Post Acute COVID-19 Syndrome
Phase 2: Dengue
Phase 1: Follicular Lymphoma|Healthy Volunteers|Immunoblastic Lymphadenopathy|Lymphoma, Non-Hodgkin|Mycosis Fungoides|T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROTECT | P2 |
Recruiting |
Dengue |
2025-06-01 |
|
| ST-001-010 | P1 |
Recruiting |
Immunoblastic Lymphadenopathy|T-Cell Peripheral Lymphoma|Mycosis Fungoides|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Follicular Lymphoma |
2025-05-01 |
|
| ESSOR | P3 |
Active, not recruiting |
Post Acute COVID-19 Syndrome |
2024-08-05 |
|
| RESOLUTION | P3 |
Completed |
COVID-19 |
2024-02-15 |